Joan B. Erland

1.1k total citations
20 papers, 891 citations indexed

About

Joan B. Erland is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Oral Surgery. According to data from OpenAlex, Joan B. Erland has authored 20 papers receiving a total of 891 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 5 papers in Oral Surgery. Recurrent topics in Joan B. Erland's work include Lung Cancer Research Studies (8 papers), Lung Cancer Treatments and Mutations (7 papers) and Lung Cancer Diagnosis and Treatment (6 papers). Joan B. Erland is often cited by papers focused on Lung Cancer Research Studies (8 papers), Lung Cancer Treatments and Mutations (7 papers) and Lung Cancer Diagnosis and Treatment (6 papers). Joan B. Erland collaborates with scholars based in United States and United Kingdom. Joan B. Erland's co-authors include John D. Hainsworth, F. Anthony Greco, Howard A. Burris, Michael Thomas, Leonard Kalman, Lisa H. Morrissey, James E. Bradof, Sharlene Litchy, Marshall T. Schreeder and Denise A. Yardley and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Annals of Oncology.

In The Last Decade

Joan B. Erland

20 papers receiving 864 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joan B. Erland United States	13	796	293	263	227	103	20	891
James E. Bradof United States	13	547 0.7×	272 0.9×	322 1.2×	66 0.3×	75 0.7×	19	874
C. Bumma Italy	16	546 0.7×	186 0.6×	87 0.3×	57 0.3×	116 1.1×	52	806
Fulvia Pedani Italy	16	522 0.7×	164 0.6×	110 0.4×	61 0.3×	135 1.3×	42	871
G. Baciarello France	7	292 0.4×	212 0.7×	119 0.5×	69 0.3×	78 0.8×	18	440
Don W. Shaffer United States	8	407 0.5×	151 0.5×	273 1.0×	32 0.1×	20 0.2×	11	678
C. Farley United States	10	397 0.5×	282 1.0×	76 0.3×	55 0.2×	65 0.6×	20	605
Francis Parnis Australia	14	328 0.4×	457 1.6×	100 0.4×	75 0.3×	160 1.6×	60	761
C Jaulerry France	15	397 0.5×	234 0.8×	125 0.5×	31 0.1×	59 0.6×	37	873
Rossella De Cecio Italy	17	393 0.5×	248 0.8×	95 0.4×	40 0.2×	117 1.1×	47	706
Viktor Gruenwald Germany	14	236 0.3×	368 1.3×	124 0.5×	18 0.1×	121 1.2×	53	586

Countries citing papers authored by Joan B. Erland

Since Specialization

Citations

This map shows the geographic impact of Joan B. Erland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joan B. Erland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joan B. Erland more than expected).

Fields of papers citing papers by Joan B. Erland

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joan B. Erland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joan B. Erland. The network helps show where Joan B. Erland may publish in the future.

Co-authorship network of co-authors of Joan B. Erland

This figure shows the co-authorship network connecting the top 25 collaborators of Joan B. Erland. A scholar is included among the top collaborators of Joan B. Erland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joan B. Erland. Joan B. Erland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Greco, F. Anthony, Dana S. Thompson, Lisa H. Morrissey, et al.. (2005). Paclitaxel/Carboplatin/Etoposide Versus Paclitaxel/Topotecan for Extensive-Stage Small Cell Lung Cancer: A Minnie Pearl Cancer Research Network Randomized, Prospective Phase II Trial. The Oncologist. 10(9). 728–733. 12 indexed citations

2.

Greco, F. Anthony, Gladys Rodriguez, Don W. Shaffer, et al.. (2004). Carcinoma of Unknown Primary Site: Sequential Treatment with Paclitaxel/Carboplatin/Etoposide and Gemcitabine/Irinotecan: A Minnie Pearl Cancer Research Network Phase II Trial. The Oncologist. 9(6). 644–652. 41 indexed citations

3.

Thompson, Dana S., John D. Hainsworth, Lisa H. Morrissey, et al.. (2004). Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive stage small cell lung cancer: A Minnie Pearl Cancer Research Network randomized prospective phase II trial. Journal of Clinical Oncology. 22(14_suppl). 7205–7205. 1 indexed citations

4.

Thompson, Dana S., John D. Hainsworth, Lisa H. Morrissey, et al.. (2004). Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive stage small cell lung cancer: A Minnie Pearl Cancer Research Network randomized prospective phase II trial. Journal of Clinical Oncology. 22(14_suppl). 7205–7205. 1 indexed citations

5.

Meluch, Anthony A., F. Anthony Greco, Howard A. Burris, et al.. (2004). Weekly paclitaxel/estramustine phosphate plus carboplatin administered either weekly or every 4 weeks in the treatment of hormone refractory prostate cancer (HRPC): A randomized phase II trial of the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology. 22(14_suppl). 4659–4659. 6 indexed citations

6.

Hainsworth, John D., Howard A. Burris, Joan B. Erland, et al.. (2003). Combination Chemotherapy with Gemcitabine and Vinorelbine in the Treatment of Patients with Relapsed or Refractory Small Cell Lung Cancer: A Phase II Trial of the Minnie Pearl Cancer Research Network. Cancer Investigation. 21(2). 193–199. 19 indexed citations

7.

Hainsworth, John D., Joan B. Erland, John H. Barton, et al.. (2003). Combination Treatment with Weekly Docetaxel and Gemcitabine for Advanced Non–Small-Cell Lung Cancer in Elderly Patients and Patients with Poor Performance Status: Results of a Minnie Pearl Cancer Research Network Phase II Trial. Clinical Lung Cancer. 5(1). 33–38. 23 indexed citations

8.

Greco, F. Anthony, Howard A. Burris, Sharlene Litchy, et al.. (2002). Gemcitabine, Carboplatin, and Paclitaxel for Patients With Carcinoma of Unknown Primary Site: A Minnie Pearl Cancer Research Network Study. Journal of Clinical Oncology. 20(6). 1651–1656. 85 indexed citations

9.

Greco, F. Anthony, James R. Gray, Dana S. Thompson, et al.. (2002). Prospective randomized study of four novel chemotherapy regimens in patients with advanced nonsmall cell lung carcinoma. Cancer. 95(6). 1279–1285. 34 indexed citations

10.

Greco, F. Anthony, Howard A. Burris, James R. Gray, et al.. (2001). Paclitaxel and carboplatin adjuvant therapy alone or with radiotherapy for resected nonsmall cell lung carcinoma. Cancer. 92(8). 2142–2147. 7 indexed citations

11.

Hainsworth, John D., Howard A. Burris, Denise A. Yardley, et al.. (2001). Weekly Docetaxel in the Treatment of Elderly Patients With Advanced Breast Cancer: A Minnie Pearl Cancer Research Network Phase II Trial. Journal of Clinical Oncology. 19(15). 3500–3505. 132 indexed citations

12.

Greco, F. Anthony, Joe W. Gray, Howard A. Burris, et al.. (2001). Taxane-based chemotherapy for patients with carcinoma of unknown primary site.. PubMed. 7(3). 203–12. 39 indexed citations

13.

Burris, Howard A., John D. Hainsworth, Joan B. Erland, et al.. (2000). Phase II trial evaluating triplet chemotherapy using gemcitabine, paclitaxel, and carboplatin in the treatment of patients with advanced non-small cell lung cancer.. PubMed. 27(1 Suppl 2). 9–13. 12 indexed citations

14.

Greco, F. Anthony, Joan B. Erland, Lisa H. Morrissey, et al.. (2000). Carcinoma of unknown primary site: Phase II trials with docetaxel plus cisplatin or carboplatin. Annals of Oncology. 11(2). 211–215. 80 indexed citations

15.

Hainsworth, John D., Howard A. Burris, Sharlene Litchy, et al.. (2000). Gemcitabine and vinorelbine in the second-line treatment of nonsmall cell lung carcinoma patients. Cancer. 88(6). 1353–1358. 36 indexed citations

16.

Greco, F. Anthony, Howard A. Burris, Joan B. Erland, et al.. (2000). Carcinoma of unknown primary site. Cancer. 89(12). 2655–2660. 4 indexed citations

17.

Hainsworth, John D., Howard A. Burris, Joan B. Erland, et al.. (1999). Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced nonsmall cell lung carcinoma. Cancer. 85(6). 1269–1276. 35 indexed citations

18.

Burris, H.A., Kathy S. Albain, Francesco Greco, et al.. (1999). Phase II trial of docetaxel and Herceptin (R) as first- or second-line chemotherapy for women with metastatic breast cancer whose tumours overexpress HER2. European Journal of Cancer. 35. S322–S322. 1 indexed citations

19.

Hainsworth, John D., Howard A. Burris, Joan B. Erland, Michael Thomas, & F. Anthony Greco. (1998). Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.. Journal of Clinical Oncology. 16(6). 2164–2168. 226 indexed citations

20.

Hainsworth, John D., Joan B. Erland, Leonard Kalman, Marshall T. Schreeder, & F. Anthony Greco. (1997). Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide.. Journal of Clinical Oncology. 15(6). 2385–2393. 97 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact